Opublikowany na Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (https://archiwum.urpl.gov.pl)

Strona główna > Produkty Lecznicze > Zalecenia dla podmiotów odpowiedzialnych

Zalecenia dla podmiotów odpowiedzialnych

Wysłane przez marpie w Czw, 31/03/2016 - 14:09

ZALECENIA DLA PODMIOTÓW ODPOWIEDZIALNYCH

Substancja czynna

Zalecenia

Podstawa prawna

Termin złożenia zmiany

Data notyfikacji decyzji Komisji Europejskiej

Klasyfikacja zmiany

17-alpha-oestradiol (topical) [1]

PSUR worksharing

-

-  

IB nr C.I.3 z)

5 fluorouracil [2]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

5-fluorouracil  [3]
(i.v. application) [3]
Stanowisko CMDh -
02/01/2019
 
  IAIN nr C.I.3 a)

99mTc-human albumin macro-aggregates [4]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Abirateron [5]

Pojedyncze sygnały   10/04/2020   IAIN nr C.I.z

Acenocoumarol [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Acetazolamid [7]

Pojedyncze sygnały

- 23/12/2017   IAIN nr C.I.z
Acetazolamid [8] Pojedyncze sygnały   25/11/2023   IAIN nr C.I.z

Acetylsalicylic acid [9]

Pediatryczny worksharing

Art. 45

Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Acitretin [10]

Stanowisko CMDh

-

05/10/2016

 

IAIN nr C.I.3 a)

Adagrazyb [11] Pojedyncze sygnały   06.07.2024   IAIN nr C.I.z
Adalimumab [12] Pojedyncze sygnały   08/04/2021   IAIN nr C.I.z

Adapalene / benzoyl peroxide [13]

Stanowisko CMDh - 12/09/2018   IAIN nr C.I.3 a)

Agomelatine [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

AirFluSal Forspiro and associated names (salmeterol xinafoate and fluticasone propionate) [15]

Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian
Aksykabtagen cyloleucel [16] Pojedyncze sygnały   05.03.2024   IAIN nr C.I.z
Aksykabtagen cyloleucel; breksukabtagen autoleucel; cyltakabtagen autoleucel; idekabtagen wikleucel; lizokaptagen maraleucel; tisagenlecleucel  [17] Pojedyncze sygnały   08.09.2024   IAIN nr C.I.z

Aksytynib [18]

Pojedyncze sygnały

-

11/06/2016

 

IAIN nr C.I.z

Albiglutide [19]

Pojedyncze sygnały

-

02/07/2017

 

IAIN nr C.I.z

Aldesleukin [20] Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Alemtuzumab [21]

Pojedyncze sygnały   01.12.2018   IAIN nr C.I.z
Alemtuzumab [22] Pojedyncze sygnały   31/07/2021   IAIN nr C.I.z
Alemtuzumab [23] Pojedyncze sygnały   04.06.2022   IAIN nr C.I.z

Allopurinol [24]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Alprostadil (erectile dysfunction) [25]

Stanowisko CMDh

-

25/01/2017

 

IAIN nr C.I.3 a)

Alprostadil (indicated in peripheral arterial occlusive diseases) [26] Stanowisko CMDh - 08/08/2018   IAIN nr C.I.3 a)

Alteplase [27]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Altizide, Spironolactone [28]

Stanowisko CMDh

-

06/01/2016

 

 IAIN nr C.I.3 a)

Abemacyklib; palbocyklib; rybocyklib [29] Pojedyncze sygnały   02.06.2024   IAIN nr C.I.z
Amfoterycyna B, tłuszczowe formuły [30] Pojedyncze sygnały   05.04.2024   IAIN nr C.I.z

Amiodarone [31]

Stanowisko CMDh

-

04/11/2015

 

IAIN nr C.I.3 a)

Amantadine [32] Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Amitriptyline [33]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Amitriptyline [34]

Pojedyncze sygnały

  07.07.2018   IAIN nr C.I.z

Amitriptyline/perphenazine [35]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide [36] Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Amlodypine [37]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Amlodipine + Atorvastatine [38]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Amlodipine besilate / Ramipril [39]

Stanowisko CMDh

-

30/03/2016

 

IAIN nr C.I.3 a)

Amoxicillin [40]

Pojedyncze sygnały

- 07/10/2017  

IAIN nr C.I.z

Amoxicillin + clavulanic acid [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Amphotericin B [41]

Pediatryczny worksharing

Art. 45

Rozp. 1901/2006

03/07/2018*

02/08/2018**

  IB nr C.I.3 z)

Ampicillin-sulbactam [42]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Anakinra [43]

Pojedyncze sygnały

-

03/01/2016

 

IAIN nr C.I.z

Anakinra, kanakinumab [44] Pojedyncze sygnały   06/07/2021   IAIN nr C.I.z
Anastrozol [12] Pojedyncze sygnały   08/04/2021   IAIN nr C.I.z

Andeksanet alfa [45]

Pojedyncze sygnały   11/07/2020   IAIN nr C.I.z

Antithrombin III [46]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Apiksaban, edoksaban [47]

Pojedyncze sygnały - 11.08.2018   IAIN nr C.I.z

Apomorphine [48]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Apomorphine [49]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Argatroban [50]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Asmanex Twisthaler (mometasone furoate) 
UK/W/0064/pdWS/005
[51]

Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Asparaginase [52]

Stanowisko CMDh

-

10/08/2016

 

IAIN nr C.I.3 a)

Atenolol / Chlortalidone [53]

Stanowisko CMDh

-

20/08/2015

 

IAIN nr C.I.3 a)

Atezolizumab; awelumab; cemiplimab; dostarlimab; durwalumab;  pilimumab; niwolumab; niwolumab z relatlimabem; pembrolizumab; tislelizumab; tremelimumab [11] Pojedyncze sygnały   06.07.2024   IAIN nr C.I.z
Atezolizumab; awelumab; cemiplimab; dostarlimab; durwalumab;  pilimumab; niwolumab; niwolumab z relatlimabem; pembrolizumab; tislelizumab; tremelimumab [11] Pojedyncze sygnały   06.07.2024   IAIN nr C.I.z

Atorvastatin [54]

 PSUR worksharing -  -    IB nr C.I.3 z)

Atorvastatin [55]

Stanowisko CMDh   10/10/2018   IAIN nr C.I.3 a)

Atovaquone and proguanil hydrochloride [56]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Atracurium [57]

PSUR worksharing -  25/01/2018   IB nr C.I.3 z)
Awatrombopag [30] Pojedyncze sygnały   05.04.2024   IAIN nr C.I.z

Azacitidine [58]

Stanowisko CMDh

-

06/04/2017

 

IAIN nr C.I.z

Azacytydyna (postać do wstrzykiwań) [59] Pojedyncze sygnały   23/12/2023   IAIN nr C.I.z

Azathioprine [18]

Pojedyncze sygnały

-

11/06/2016

 

IAIN nr C.I.z

Azatiopryna [60] Pojedyncze sygnały   03/07/2021   IAIN nr C.I.z

Azithromycin (systemic use formulation) [61]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Azytromycyna; klarytromycyna; erytromycyna; roksytromycyna [7]

Pojedyncze sygnały

- 23/12/2017   IAIN nr C.I.z

Bazedoksyfen + Estrogen [62]

Pojedyncze sygnały

-

06/04/2016

 

IAIN nr C.I.z

Bacillus clausii multi-antibioresistant spores [63]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Baclofen (oral) [64]

Stanowisko CMDh

-

04/10/2017

 

IAIN nr C.I.3 a)

Barycytynib [65] Pojedyncze sygnały   23/08/2020   IAIN nr C.I.z
Barycytynib [66] Pojedyncze sygnały   10.08.2024   IAIN nr C.I.z

BCG vaccine (freeze-dried) [67]

Stanowisko CMDh - 27/02/2019   IAIN nr C.I.3 a)

Beclomethasone (excluding cutaneous formulations) [68]

Pojedyncze sygnały

-

21/02/2017

 

IAIN nr C.I.z

Bemetizide / Triamterene [69]

Stanowisko CMDh

-

08/06/2016

 

IAIN nr C.I.3 a)

Benazepril [70]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Bendamustine/hydrochloride [71]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Bendamustine hydrochloride  [72]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)
Bendroflumethiazide, bendroflumethiazide / potassium chloride [73] Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Benzydamine [74]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Berinert (C1-esterase inhibitor, human)  [75]
DE/W/0051/pdWS/003 [75]
Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Bilastine [76]

Stanowisko CMDh

-

24/01/2017

 

IAIN nr C.I.3 a)

Bilastine [77]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Bismuth subcitrate potassium / Metronidazole / Tetracycline [78]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Bismuth subcitrate potassium /metronidazole /tetracycline [79]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Boceprevir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Bosutynib [80] Pojedyncze sygnały   06.05.2023   IAIN nr C.I.z

Botulinum neurotoxin type a (150 d) free from complexing proteins [81]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Botulinum toxin a - haemagglutinin complex  [82]

Stanowisko CMDh

-

18/12/2016

 

IAIN nr C.I.3 a)

Botulinum toxin a [83]

Stanowisko CMDh

-

18/12/2016

 

IAIN nr C.I.3 a)

Brentuximab vedotin [84]

Pojedyncze sygnały

-

29/07/2017

 

IAIN nr C.I.z

Bromazepam [85]

PSUR worksharing - 23/01/2018   IB nr C.I.3 z)

Brotizolam [86]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Budesonide  [87]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Budesonide [88]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Budesonide + Formoterol [89]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Buflomedil hydrochloride [90]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Bumetadine [91]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
03/12/2018* 
31/12/2018**
  IB nr C.I.3 z)
Buprenorfina; buprenorfina, nalokson [65] Pojedyncze sygnały   23/08/2020   IAIN nr C.I.z

Buprenorphine [92]

PSUR worksharing

-

11/04/2017

 

IB nr C.I.3 z)

Bupropion [93]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Cabergoline [94]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Calcium carbonate / famotidine / magnesium hydroxide [95]

Stanowisko CMDh - 12/09/2018   IAIN nr C.I.3 a)

Calcium carbonate, Famotidine, Magnesium hydroxide [96]

                       Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Calcium carbonate + Cholecalciferol [97]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Calcium chloride dihydrate, Sodium chloride, Sodium (S)-lactate solution, Magnesium chloride hexahydrate, Glucose monohydrate [98]

PSUR worksharing - Bez konieczności złożenia zmian   Bez konieczności złożenia zmian

Calcium valproate [99]

Stanowisko CMDh

-

                           06/01/2016

 

IAIN nr C.I.3 a)

Candesartan/Candesartan+ Hydrochlorothiazide [100]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Candesartan, 
Candesartan /hydrochlorothiazide
[101]

Stanowisko CMDh - 08/05/2018   IAIN nr C.I.3 a)

Captopril / Hydrochlorothiazide [102]

Stanowisko CMDh

-

23/03/2017

 

IAIN nr C.I.3 a)

Captopril + Hydrochlorothiazide [103]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Carboplatin [104]

Stanowisko CMDh

-

25/01/2017

 

IAIN nr C.I.3 a)

Carbidopa/levodopa [105]

Stanowisko CMDh

-

04/10/2017

 

IAIN nr C.I.3 a)

Carmustine (powder and solvent for solution for infusion) [106]

Stanowisko CMDh

-

30/03/2016

 

IAIN nr C.I.3 a)

Carteolol [107]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Cefadroxil [108]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)

Cefalexin [109]

Pojedyncze sygnały  - 03.06.2018   IAIN nr C.I.z
Cefatoksym [30] Pojedyncze sygnały   05.04.2024   IAIN nr C.I.z

Cefepime [110]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ceftriakson [111] Pojedyncze sygnały   23.01.2021   IAIN nr C.I.z

Cefoperazone/sulbactam [112]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Cefoperazone [113]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Cefotaxime [114]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Cefuroxime sodium (except for intracameral use) [115]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Ceftazidime [116]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Certican (everolimus) 
SE/W/0025/pdWS/003
[117]

Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Cetirizine [118]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Certizne / pseudoephedrine [119]

Stanowisko CMDh

-

30/08/2017

 

IAIN nr C.I.3 a)

Cisplatin [120]

Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)
Chloroheksydyna do stosowania na skórę, wskazana do odkażania skóry, i odpowiednie skojarzenia leków o ustalonych dawkach [11] Pojedyncze sygnały   06.07.2024   IAIN nr C.I.z

Chlormadinone [121]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)
Chlorochina, hydroksychlorochina [122] Pojedyncze sygnały   06.03.2021   IAIN nr C.I.z

Chloroquine [123]

Stanowisko CMDh

-

14/07/2016

 

IAIN nr C.I.3 a)

Chloroquinaldol (vaginal tablet) / promestriene [124]

Stanowisko CMDh

-

30/08/2017

 

IAIN nr C.I.3 a)

Chlorpromazine [125]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Chlorprothixene hydrochloride [126]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Cholekalcyferol [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Ciclopirox olamine (shampoo only) [128]

PSUR worksharing - Nie dotyczy   Bez konieczności złożenia zmian

Ciclosporin [129]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Cilazapril, cilazapril / hydrochlorothiazide [130]

Stanowisko CMDh - 30/01/2019   IAIN nr C.I.3 a)

Cilostazol [131]

Stanowisko CMDh

-

03/02/2016

 

 IAIN nr C.I.3 a)

Ciprofloxacin [132]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ciprofloxacin [133]

Stanowisko CMDh - 30/01/2019   IAIN nr C.I.3 a)
Ciprofloxacin Decyzja Komisji Europejskiej art. 31   12/03/2019 IAIN nr C.I.1 a)/
IB nr C.I.1 b

Ciprofloxacin (solutions for infusion) [40]

Pojedyncze sygnały

-

07/11/2017

 

IAIN nr C.I.z

Citalopram; deswenlafaksyna; escytalopram; fluoksetyna fluwoksamina; milnacypran; paroksetyna; sertralina; wenlafaksyna; wortioksetyna [134]

Pojedyncze sygnały   26.12.2020   IAIN nr C.I.z

Ciprofloxacin hydrochloride + Dexamethasone acetate (ear drops, suspension) [135]

                                 PSUR worksharing

-

-

 

IB nr C.I.3 z)

Clarithromycin [136]

PSUR worksharing

-

11/09/2016

 

IB nr C.I.3 z)

Clarithromycin [137]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Clebopride [138]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Clevidipine [139]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Clodronate [140]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Clostridium botulinium neurotoxin type A haemagglutinin complex [141]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Clostridium botulinum toxin [142] Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
06/08/2018* 
05/09/2018**
  IB nr C.I.3 z)

Cobicistat [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Codeine [143]

Stanowisko CMDh

Art. 31

20/07/2015

 

IB nr C.I.1 a) lub IB nr C.I.1 b)

Comirnaty [144] Pojedyncze sygnały   01.11.2021   IAIN nr C.I.z

Corticorelin [145]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Corticosteroids other than beclomethasone (excluding cutaneous formulations) [68]

Pojedyncze sygnały

-

21/02/2017

 

IAIN nr C.I.z

Cyproheptadine [146]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Cyproterone acetate/Ethinylestradiol [147]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dabrafenib; trametynib [148] Pojedyncze sygnały   06/04/2023   IAIN nr C.I.z
           

Daclatasvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Daklataswir [149]

Pojedyncze sygnały

-

13/06/2015

 

IAIN nr C.I.z

Danaparoid [150]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dapagliflozyna; Dapagliflozyna z metforminą; Dapagliflozyna z saksagliptyną [151] Pojedyncze sygnały   20/01/2024   IAIN nr C.I.z

Dapoxetine [152]

Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Darbepoetin alfa [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Dasabuvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Daunorubicin [153]

Stanowisko CMDh

-

08/06/2016

 

IAIN nr C.I.3 a)

Dazatynib [154]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Dazatynib [34]

Pojedyncze sygnały

- 07.07.2018   IAIN nr C.I.z
Dabrafenib, trametynib [111] Pojedyncze sygnały   23.01.2021   IAIN nr C.I.z
Dabrafenib; Trametynib [16] Pojedyncze sygnały   05.03.2024   IAIN nr C.I.z
Dabrafenib w połączeniu z trametinibem; dabrafenib w monoterapii; produkty lecznicze: Tafinlar; Finlee; Mekinist; Spexotras [66] Pojedyncze sygnały   10.08.2024   AIN nr C.I.z

Dekslanzoprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Delapril [156]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Delapril / manidipine, delapril /inapamide [157]

Stanowisko CMDh - 21/06/2018   IAIN nr C.I.3 a)

Deoxycholic acid [158]

PSUR worksharing - 18/02/2018   IB nr C.I.3 z)

Deoxycholic acid [159]

Stanowisko CMDh   10/10/2018   IAIN nr C.I.3 a)

Deoxycholic acid [160]

Stanowisko CMDh - 27/03/2019   IAIN nr C.I.3 a)

Deoxyribonuclease human (dornase alpha) [161]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Desloratadyna, loratadyna [7]

Pojedyncze sygnały - 23/12/2017   IAIN nr C.I.z

Desogestrel [162]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dexamethasone (apart from centrally authorised products) [163]

Stanowisko CMDh

-

02/02/2017

 

IAIN nr C.I.3 a)

Dexamfetamine [164]

Stanowisko CMDh - 08/08/2018   IAIN nr C.I.3 a)

Dexlansoprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Dexlansoprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Dexlansoprazole, lansoprazole [166]

Stanowisko CMDh - 28/12/2017   IAIN nr C.I.3 a)

Dexibuprofen [167]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dexketoprofen [168]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dextromethorphan [169]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Dezogestrel [170] Pojedyncze sygnały   06/09/2020   IAIN nr C.I.z

Diacerein [171]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Diclofenac /misoprostol [172]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)

Diclofenac (systemic formulations) [173]

Stanowisko CMDh

-

07/09/2016

 

IAIN nr C.I.3 a)

Didanosine [174]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dinoprostone [175]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Diovan and related names (valsartan) [176]

Pediatryczny worksharing

Art. 46
Rozp. 1901/2006

24/11/2017*
24/12/2017**

  IB nr C.I.3 z)

Diovan and related names (valsartan)
SE/W/0026/pdWS/002
[177]

Pediatryczny worksharing

Art. 46
Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Doksycyklina [7]

Pojedyncze sygnały    23/12/2017   IAIN nr C.I.z

Dolutegrawir [178]

Pojedyncze sygnały   

29.12.2018

 

IAIN nr C.I.z

Domperidone [179]

Stanowisko CMDh

-

01/11/2017

 

IAIN nr C.I.3 a)

Donepezil [155]

Pojedyncze sygnały

-

07/10/2015

 

IAIN nr C.I.z

Dorzolamide [180]

Stanowisko CMDh

-

22/02/2017

 

IAIN nr C.I.3 a)

Dorzolamide + Timolol [181]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Doxazosin [182]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Doxylamine [183]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Doxycycline [184]

Pediatryczny worksharing Art. 45 
Rozp. 1901/2006
01/05/2018* 
31/05/2018**
  IB nr C.I.3 z)

Drospirenone and Ethinylestradiol [185]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Dulaglutyd [186]

Pojedyncze sygnały  - 05/04/2018   IAIN nr C.I.z

Duloksetyna [21]

Pojedyncze sygnały

  01.12.2018   IAIN nr C.I.z
Durwalumab [187] Pojedyncze sygnały   21/01/2023   IAIN nr C.I.z
Durvalumab [188] Pojedyncze sygnały   07.04.2022   IAIN nr C.I.z

Dutasteride [189]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ebastine [190]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Econazole [191]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Elasomeran (szczepionka mRNA przeciwko COVID-19 — Spikevax) [23] Pojedyncze sygnały   8.04.2022   IAIN nr C.I.z
Elasomeran (Szczepionka mRNA przeciwko COVID-19 – Spikevax) [187] Pojedyncze sygnały   25/11/2022   IAIN nr C.I.z

Elbasvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Enalapril [192]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Enoxacin Decyzja Komisji Europejskiej art. 31   12/03/2019  IAIN nr C.I.1 a)/
IB nr C.I.1 b)
Enzalutamid [193] Pojedyncze sygnały   07/05/2022   IAIN nr C.I.z

Epinastine [194]

Stanowisko CMDh   10/10/2018   IAIN nr C.I.3 a)

Epinastine hydrochloride [195]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Epirubicin [196]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Epoetin alfa [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Epoetin beta [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Epoetin theta [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Epoetin zeta [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Epoprostenol [197]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Eprosartan hydrochlorothiazide [198]

PSUR worksharing - 05/03/2018   IB nr C.I.3 z)

Eprosartan mesylate [199]

PSUR worksharing - 05/03/2018   IB nr C.I.3 z)
Ertapenem [200] Pojedyncze sygnały   22.01.2022   IAIN nr C.I.z

Erythromycin and erythromycin in combination (topical) [201]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Esomeprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Esomeprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Estradiol valerate + Dienogest [202]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Estradiol + Norethisterone [203]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Estrogen [62]

Pojedyncze sygnały

-

06/04/2016

 

IAIN nr C.I.z

Estrogen + Progestagen [62]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Estrogen + Progestagen [62]

Pojedyncze sygnały

-

06/04/2016

 

IAIN nr C.I.z

Etambutol [11] Pojedyncze sygnały   06.07.2024   IAIN nr C.I.z

Ethinylestradiol + Dienogest [204]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ethinylestradiol + Levonorgestrel [205]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ethinylestradiol / gestodene (tranasdermal applicatation) [206]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Etomidate [207]

PSUR worksharing

-

23/10/2017

 

IB nr C.I.3 z)

Etomidate [208]

Stanowisko CMDh - 12/09/2018   IAIN nr C.I.3 a)

Etoposide phosphate

Decyzja Komisji Europejskiej art. 30 - 27.06.2017 r. IB nr C.I.1 b)

Etrogen [62]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Everolimus (indicated for rejection of transplanted organs) [209]

Stanowisko CMDh

-

14/07/2016

 

IAIN nr C.I.3 a)

Ezetimibe [210]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ezetimibe /rosuvastatin [211]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)

Ezetimibe /simvastatin [212]

PSUR worksharing - 01/05/2018   IB nr C.I.3 z)

Ezomeprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Famotidine [213]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Famotidine [214]

Stanowisko CMDh - 12/09/2018   IAIN nr C.I.3 a)

Felbamate [215]

Stanowisko CMDh

-

04/10/2017

 

IAIN nr C.I.3 a)

Felodipine + Ramipril [216]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fenoterol hydrobromide + Ipratropium bromide [217]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fenprokumon [34]

Pojedyncze sygnały - 07.07.2018   IAIN nr C.I.z

Fenspiride [218]

Stanowisko CMDh - 27/02/2019   IAIN nr C.I.3 a)

Fentanyl [219]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ferrous sulfate [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Ferumoxsil [220]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Filgrastym; lenograstym; lipegfilgrastym; pegfilgrastym [221]

Pojedyncze sygnały - 05.05.2018    

Finasteride [222]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Finasteride [223]

Stanowisko CMDh

-

03/08/2017

 

IAIN nr C.I.3 a)

Finasteride [224] Stanowisko CMDh - 08/08/2018   IAIN nr C.I.3 a)

Fingolimod [225]

Pojedyncze sygnały

-

01/08/2015

 

IAIN nr C.I.z

Fixed combination containing: Dimethyl sulfoxide,Camphor, Tterebinthini aetheroleum,Benzyl nicotinate, Nonivamide [226]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Flubendazole [227]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Flucloxacillin [68]

Pojedyncze sygnały

-

21/02/2017

 

IAIN nr C.I.z

Fluconazole [228]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fluconazole [229]

Pojedyncze sygnały

-

06/05/2017

 

IAIN nr C.I.z

Fluids containing carbohydrates (intravenous) [40]

Pojedyncze sygnały

-

07/02/2018

 

IAIN nr C.I.z

Fluids containing electrolytes (intravenous) [40]

Pojedyncze sygnały

-

07/02/2018

 

IAIN nr C.I.z

Fluindione [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Flukloksacylina [7]

Pojedyncze sygnały - 23/12/2017   IAIN nr C.I.z

Flumazenil [230]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fluorochinolony do stosowania ogólnego i wziewnego  [21]

Pojedyncze sygnały

  01.12.2018   IAIN nr C.I.z

Fluorodopa (18F) [231]

Stanowisko CMDh - 27/02/2019   IAIN nr C.I.3 a)

Fluoxetine [232]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fluticasone [233]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fluticasone propionate [234]

Stanowisko CMDh - 21/02/2018   IAIN nr C.I.3 a)

Fluvoxamine [235]

PSUR worksharing - 04/07/2018   IB nr C.I.3 z)

Fluvastatin [236]

Stanowisko CMDh - 12/09/2018   IAIN nr C.I.3 a)

Folic acid [237]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Folinic acid / (di)sodium folinate / Calcium folinate / Calcium levofolinate [238]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Formoterol [239]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Fulvestrant [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Fumaran dimetylu (Tecfidera) [21]

Pojedyncze sygnały

  01.12.2018   IAIN nr C.I.z

Furosemide/Spironolactone [240]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Furosemide [241]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Fusidic acid and Sodium fusidate [242]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Gabapentin [243]

Stanowisko CMDh

-

25/01/2017

 

IAIN nr C.I.3 a)

Gabapentin [244]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Gabapentin [245]

Pojedyncze sygnały

-

03/09/2017

 

IAIN nr C.I.z

Gadobenic acid [246]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadobenic acid

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadobutrol [247]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadobutrol

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 r. IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadodiamid [248]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Gadodiamide [249]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadodiamide

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadopentetic acid dimeglumine [250]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Gadopentetic acid [251]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadopentetic acid

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadoteric acid (IV and intravascular formulations) [252]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadoteric acid

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 r. IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadoteridol [253]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gadoteridol [254]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Gadoteridol

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadoxetic acid

Decyzja Komisji Europejskiej art. 31 - 24/11/2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Gadoxetic acid disodium [255]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Gemcitabine [256]

Stanowisko CMDh - 02/01/2019   IAIN nr C.I.3 a)

Gentamicin (systemic use) [257]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)
Genotropin and associated names (somatropin) 
DK/W/008/pdWS/007
[258]
Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
24/11/2018*
24/12/2018**
   IB nr C.I.3 z)

Gilnacipran [259]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Glatiramer [260]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Glibenclamide / Metformin hydrochloride [261]

Stanowisko CMDh

-

08/06/2016

 

IAIN nr C.I.3 a)

Glucosamine [262]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Glycopyrronium bromide [263]

(all indications except for chronic obstructive pulmonary disease) [264]

Stanowisko CMDh

-

07/09/2016

 

IAIN nr C.I.3 a)

Glycopyrronium / Neostigmine [265]

Stanowisko CMDh

-

07/09/2016

 

IAIN nr C.I.3 a)

Golimumab [5]

Pojedyncze sygnały   10/04/2020   IAIN nr C.I.z

Granisetron (other formulations except for transdermal patch) [266]

Stanowisko CMDh

-

22//02/2017

 

IAIN nr C.I.3 a)

Grazoprevir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Haemophilus type b
conjugate vaccines
[267]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Haloperidol decanoate

Decyzja Komisji Europejskiej art. 30 - 02.05.2017 IB nr C.I.1 b)

Haloperidol

Decyzja Komisji Europejskiej art. 30 - 02/05/2017 IB nr C.I.1 b)

Haloperidol

korekta Decyzji Komisji Europejskiej art. 30 - 13/06/2017 IB nr C.I.1 b)
Havrix Junior 720 (inactivated Hepatitis A virus antigen) [268] Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
-
Nie dotyczy
Bez konieczności złożenia zmian
Hormonalna terapia zastępcza (HTZ): chlorotrianizen; skoniugowane estrogeny; skoniugowane estrogeny, bazedoksyfen; dienestrol; dietylostylbestrol; estradiol; estradiol, noretysteron; estriol; estron; etynyloestradiol; metalenestryl; moksestrol; promestrien; tibolon [65] Pojedyncze sygnały   23/09/2020   IAIN nr C.I.z
Hormonalna terapia zastępcza (HTZ): tibolon [170] Pojedyncze sygnały   06/09/2020   IAIN nr C.I.z

Hormonalne środki antykoncepcyjne [178]

(Chlormadynon, estradiol; octan chlormadynonu, etynyloestradiol ; estrogeny skoniugowane, medrogeston; estrogeny skoniugowane, octan medroksyprogesteronu; estrogeny skoniugowane, norgestrel; cyproteron, etynyloestradiol; octan cyproteronu,walerianian estradiolu; dezogestrel; dezogestrel ,etynyloestradiol; dienogest, estradiol; dienogest, etynyloestradiol; drospirenon, estradiol; drospirenon, etynyloestradiol; estradiol, estriol, lewonorgestrel; estradiol, gestoden; estradiol, lewonorgestrel; estradiol, octan medroksyprogesteronu; estradiol, octan nomegestrolu; estradiol, noretysteron; estradiol, norgestymat; estradiol (17-beta), progesteron; estradiol (17-beta), trimegeston; walerianian estradiolu, norgestrel; etynyloestradiol, etonogestrel; etynyloestradiol, etynodiol; etynyloestradiol, gestoden; etynyloestradiol, gestoden; etynyloestradiol, lewonorgestrel; etynyloestradiol, linestrenol; etynyloestradiol, noretysteron; [178]

etynyloestradiol, norgestymat; etynyloestradiol, norgestrel; lewonorgestrel, etynyloestradiol; etynyloestradiol; lewonorgestrel; medroksyprogesteron; mestranol, noretysteron; nomegestrol; octan nome gestrolu estradiol; norelgestromin, etynyloestradiol; noretysteron [178]

Pojedyncze sygnały

 

29.12.2018

 

IAIN nr C.I.z

Human coagulation factor VII [269]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Human coagulation factor VIII

Decyzja Komisji Europejskiej art. 31 - 13.11.2017 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Human coagulation factor VIII inhibitor bypassing fraction [270]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Human coagulation factor VIII inhibitor bypassing fraction [271]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Human fibirinogen [272]

PSUR worksharing - 31/12/2018   IB nr C.I.3 z)

Humatrope (somatropin) NL/W/0007/pdWS/002 [273]

Pediatryczny worksharing

Art. 46

Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Humatrope(somatropin) 
NL/W/0007/pdWS/003
[274]

Pediatryczny worksharing

Art. 46

Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Humatrope(somatropin)
NL/W/0007/pdWS/004
[275]

Pediatryczny worksharing

Art. 46

Rozp. 1901/2006

03/06/2018*

03/07/2018**

  IB nr C.I.3 z)

Humatrope (somatropin)
NL/W/0007/pdWS/005
[276]

Pediatryczny worksharing

Art. 46

Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Priorix (measles, mumps and rubella vaccine)
DE/W/0055/pdWS/004
[277]

Pediatryczny worksharing

Art. 46

Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Hydrochlorothiazide, Spironolactone [278]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Hydrochlorotiazyd [21]

Pojedyncze sygnały

  01.12.2018   IAIN nr C.I.z
Hydrokortyzon [12] Pojedyncze sygnały   08/04/2021   IAIN nr C.I.z

Hydroksykarbamid [221]

Pojedyncze sygnały  - 05.05.2018   IAIN nr C.I.z

Hydromorphone [279]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Hydroquinidine [280]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Hydroxyzine [281]

Stanowisko CMDh

Art. 31

19/06/2015

 

IB nr C.I.1 a) lub IB nr C.I.1 b)

Hydroxycarbamide (except for centrally authorised product) [282]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)
Ibrutynib [111] Pojedyncze sygnały   23.01.2021   IAIN nr C.I.z

Ibuprofen- and dexibuprofen [283]

Stanowisko CMDh

Art. 31

16/10/2015

 

IB nr C.I.1 a) lub IB nr C.I.1 b)

Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus) [284]

Stanowisko CMDh - 21/02/2018    IAIN nr C.I.3 a)

Ibuprofen, ketoprofen i produkty złożone o stałej dawce do stosowania ogólnego [45]

Pojedyncze sygnały   11/11/2020   IB C.I.z

Ibuprofen / pseudoephedrine [285]

Stanowisko CMDh - 06/06/2018   IAIN nr C.I.3 a)

Ibutilide [286]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Idarubicin [287]

PSUR worksharing

-

-

 

 IB nr C.I.3 z)

Idelalizyb [45]

Pojedyncze sygnały   11/07/2020   IAIN nr C.I.z

Imatynib [154]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Imipenem/cilastatin [288]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Immunoglobulina ludzka normalna do podawania dożylnego [289]

Pojedyncze sygnały

  06.11.2018   IAIN nr C.I.z

Inactivated hepatitis A virus antigen [290]

Pediatryczny worksharing

Art. 45
Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian

Inactivated influenza split trivalent vaccine [291]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Indium (In-111) chloride solution [292]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

 Indobufen [293]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Infanrix [294]

Pediatryczny worksharing Art. 45
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Influenza vaccine (surface antigen, inactivated) [295]

Stanowisko CMDh

-

-

 

IAIN nr C.I.3 a)

Inhibitory immunologicznych punktów kontrolnych: atezolizumab, cemiplimab, durwalumab [296] Pojedyncze sygnały   Pojedyncze sygnały   IAIN nr C.I.z
Inhibitory czynnika martwicy nowotworu alfa: adalimumab; certolizumab pegol; etanercept; golimumab; infliksymab [297] Pojedyncze sygnały   03/10/2020   IAIN nr C.I.z
Inhibitory kalcyneuryny do stosowania ogólnoustrojowego (cyklosporyna, takrolimus) i inhibitory ssaczego celu rapamycyny (mTOR) do stosowania ogólnoustrojowego (ewerolimus, syrolimus, temsyrolimus) [23] Pojedyncze sygnały   04.06.2022   IAIN nr C.I.z

Inhibitory reduktazy 3-hydroksy-3-metylo-glutarylo-koenzymu A (HMG-CoA) (statyny): atorwastatyna; fluwastatyna; lowastatyna; pitawastatyna; prawastatyna; rozuwastatyna; symwastatyna i inne istotne skojarzenia ustalonych dawek; prawastatyna, fenofibrat; symwastatyna, fenofibrat [148]

Pojedyncze sygnały   06/04/2023   IAIN nr C.I.z

Insulin (pre-filled pens and cartridges) [298]

Pojedyncze sygnały

-

28/07/2017

 

IAIN nr C.I.z

Insulina (wstrzykiwacze napełnione i wkłady); insulina aspart, insulina bydlęca; insulina degludec; insulina; liraglutyd; insulina detemir; insulina glargine, insulina glulizynowa; insulina ludzka (rDNA), insulina izofanowa; insulina listro; insulina wieprzowa  [299]

Pojedyncze sygnały  - 04/03/2018   IAIN nr C.I.z

Insulina (dot. wszystkich produktów zawierających insulinę) [45]

Pojedyncze sygnały   11/07/2020   IAIN nr C.I.z

Interferon alfa-2a [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Interferon alfa-2a [300]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Interferon alpha-2a [301]

Stanowisko CMDh - 06/06/2018   IAIN nr C.I.3 a)

Interferon alfa-2b [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Interferon beta-1a [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Interferon beta-1b [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Iobitridol [302]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Iodine (131i) Iobenguane [303]

Stanowisko CMDh

-

07/09/2016

 

IAIN nr C.I.3 a)

Iomeprol [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Ipilimumab [21]

Pojedyncze sygnały

  01.12.2018   IAIN nr C.I.z

Ipratropium [304]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ipratropium + Salbutamol [305]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ipratropium / salbutamol [306]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Irinotecan [307]

PSUR worksharing - 18/02/2018   IB nr C.I.3 z)

Irinotecan (except for liposomal formulation) [308]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Iron parenteral preparations [309]

Stanowisko CMDh   03/12/2018   IAIN nr C.I.3 a)

Isoniazid [310]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Isotretinoin (oral formulations) [311]

Stanowisko CMDh - 01/11/2017   IAIN nr C.I.3 a)

Isotretinoin (oral formulations) [312]

Stanowisko CMDh - 27/03/2019   IAIN nr C.I.3 a)

Isradipine [313]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ivermectin [314]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ivermectin (topical use) [315]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Ivermectin (topical use) [316]

Stanowisko CMDh

-

29/03/2017

 

IAIN nr C.I.3 a)

Kapecytabina [122] Pojedyncze sygnały   06.03.2021   IAIN nr C.I.z

Karbidopa [154]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Ketamine [317]

Pediatryczny worksharing

Art. 45
Rozp. 1901/2006

24/12/2017*
23/01/2018**

  IB nr C.I.3 z)

Ketoprofen (except topical use) [318]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ketoprofen for topical use [319]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Kladrybina [7]

Pojedyncze sygnały - 23/12/2017   IAIN nr C.I.z
Klindamycyna do stosowania ogólnego  [22] Pojedyncze sygnały   31/07/2021   IAIN nr C.I.z
Kobimetynib, wemurafenib [30] Pojedyncze sygnały   05.04.2024   IAIN nr C.I.z
Kodeina, ibuprofen [320] Pojedyncze sygnały   24/12/2022   IAIN nr C.I.z
Kolistymetat sodowy do podawania dożylnego [80] Pojedyncze sygnały   06.05.2023   IAIN nr C.I.z
Koniugat trastuzumabu z emtanzyną [44] Pojedyncze sygnały   06/06/2021   IAIN nr C.I.z

Kwas alendronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas etydronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas ibandronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas klodronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas nerydronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas pamidronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas ryzedronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas tioktynowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas tyludronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Kwas zoledronowy [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Ksylometazolina [321]

Pojedyncze sygnały -

26.02.2019

 

IAIN nr C.I.z

Labetalol [322]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Labetalol [200] Pojedyncze sygnały   22.01.2022   IAIN nr C.I.z

Lamotrigine [323]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lamotrigine [324]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)
Lamotrygina [111] Pojedyncze sygnały   23.01.2021   IAIN nr C.I.z

Landiolol hydrochloride [325]

PSUR worksharing - 20/03/2018   IB nr C.I.3 z)

Lansoprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Lansoprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Lanthanum [326]

Stanowisko CMDh - 28/03/2018   IAIN nr C.I.3 a)

Lanzoprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Lapatynib [34]

Pojedyncze sygnały

- 07.07.2018   IAIN nr C.I.z

Latanoprost [225]

Pojedyncze sygnały

-

01/08/2015

 

IAIN nr C.I.z

Latanoprost/Timolol [327]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ledipasvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Ledipaswir [149]

Pojedyncze sygnały

-

13/06/2015

 

IAIN nr C.I.z

Leflunomide [19]

Pojedyncze sygnały

-

02/07/2017

 

IAIN nr C.I.z

Leflunomid [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Leflunomid [225]

Pojedyncze sygnały

-

01/08/2015

 

IAIN nr C.I.z

Leki przeciwretrowirusowe [289]

Pojedyncze sygnały

- 06.11.2018   IAIN nr C.I.z
Leki przeciwwirusowe o działaniu bezpośrednim (DAAV) wskazanym w leczeniu wirusowego zapalenia wątroby typu C [178]
(Daklatazwir; dazabuwir; elbazwir, grazoprewir; glekaprewir, pibrentazwir; ledipazwir, sofosbuwir; ombitazwir, paryteprewir, rytonawir; sofosbuwir; sofosbuwir, welpatazwir; sofosbuwir, welpatazwir, woksylaprewir) [178]
Pojedyncze sygnały - 29.12.2018  

IAIN nr C.I.z

Lenalidomid [47]

Pojedyncze sygnały - 11.08.2018   IAIN nr C.I.z

Lenograstim [328]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lenwatynib [200] Pojedyncze sygnały   22.01.2022   IAIN nr C.I.z
Lenwatynib [329] Pojedyncze sygnały   05/08/2023   AIN nr C.I.z

Lenograstim [330]

Stanowisko CMDh - 01/11/2017   IAIN nr C.I.3 a)

Lenograstym, lipegfilgrastym, pegfilgrastym [47]

Pojedyncze sygnały - 11.08.2018   IAIN nr C.I.z

Letrozole [331]

Stanowisko CMDh

-

04/10/2017

 

IAIN nr C.I.3 a)

Leuprorelin [332] Stanowisko CMDh - 08/08/2018   IAIN nr C.I.3 a)

Levetiracetam (oral solution) [333]

Pojedyncze sygnały

-

25/12/2016

 

IAIN nr C.I.z

Levobunolol (dotyczy tylko wskazań okulistycznych) [334]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Levobupivacaine [335]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Levocetirizine [336]

PSUR worksharing

-

-

 
IB nr C.I.3 z)

Levocetirizine [337]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)
Levofloxacin  Decyzja Komisji Europejskiej art. 31   12/03/2019

IAIN nr C.I.1 a)/

IB nr C.I.1 b)

Levonorgestrel [338]

Stanowisko CMDh - 02/01/2019   IAIN nr C.I.3 a)

Levosimendan [339]

PSUR worksharing

-

-

 

 IB nr C.I.3 z)

Lewodopa [154]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Lidocaine hydrochloride [340]

Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian
Lisdeksmetamina [297] Pojedyncze sygnały   03/10/2020   IAIN nr C.I.z
Lomefloxacin  Decyzja Komisji Europejskiej art. 31   12/03/2019

IAINnr C.I.1 a)/

IB nr C.I.1 b)

Lomustine [341]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Loratidine [342]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lorazepam [343]

Stanowisko CMDh - 30/01/2019   IAIN nr C.I.3 a)

Lormetazepam [344]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Loperamide [345]

Pojedyncze sygnały

-

04/06/2017

 

IAIN nr C.I.z

Losartan + Hydrochlorothiazide [346]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lovastatin [347]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lubiprostone [348]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Lymecycline [349]

Pediatryczny worksharing Art. 45 
Rozp. 1901/2006
01/04/2018* 
01/05/2018**
  IB nr C.I.3 z)

Macrogol 4000 [350]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Macrogol 4000 and combinations [351]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Magnesium hydroxide [352]

Stanowisko CMDh - 01/11/2017   IAIN nr C.I.3 a)
Magnesium valproate Decyzja Komisji Europejskiej Art. 31 - 01/06/2018 IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub

IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)
Manidypina [66] Pojedyncze sygnały   10.08.2024   IAIN nr C.I.z

Mefloquine [353]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Mefloquine [354]

Stanowisko CMDh - 21/02/2018   IAIN nr C.I.3 a)

Meloxicam [355]

Stanowisko CMDh

-

05/07/2017

 

IAIN nr C.I.3 a)

Mepivacaine, mepivacaine/adrenaline, mepivacaine hydrochloride/dextrose monohydrate [356]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Merkaptopuryna [18]

Pojedyncze sygnały

-

11/06/2016

 

IAIN nr C.I.z

Meropenem (solutions for infusion) [40]

Pojedyncze sygnały

 

07/11/2017

 

IAIN nr C.I.z

Meropenem [357]

Stanowisko CMDh

-

10/08/2016

 

IAIN nr C.I.3 a)

Mesalazine [358]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Mesalazyna [359]

Pojedyncze sygnały

- 25/11/2017   IAIN nr C.I.z
Metamizole sodium Decyzja Komisji Europejskiej art. 31   20/03/2019

IAINnr C.I.1 a)/

IB nr C.I.1 b)

Methylaminolevulinate [360]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)

Methoxy polyethylene glycol-epoetin beta [40]

Pojedyncze sygnały

 

07/10/2017

 

IAIN nr C.I.z

Methyl salicylate /levomenthol [361]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Methyl salicylate /levomenthol /DL-camphor [362]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Methylphenidate [6]

Pojedyncze sygnały

 

03/03/2017

 

IAIN nr C.I.z

Methylphenidate hydrochloride [363]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Methylprednisolone [364]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Methylprednisolone (intravenous/intramuscular use) [365]

Stanowisko CMDh

Art. 31

29/09/2017

 

IB nr C.I.1 a) lub IB nr C.I.1 b)

Metoclopramide [366]

Stanowisko CMDh

-

05/10/2016

 

IAIN nr C.I.3 a)

Metotreksat [186]

Pojedyncze sygnały - 05.04.2018   IAIN nr C.I.z
Metotreksat [367] Pojedyncze sygnały - 30.11.2021   IAIN nr C.I.z

Metronidazole [333]

Pojedyncze sygnały

 

25/12/2016

 

IAIN nr C.I.z

Miconazole / Hydrocortisone, miconazole nitrate /Miconazole nitrate, zinc oxide [368]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Mifepristone /misoprostol [369]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)

Milnacipran [370]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Milnacipran [371]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Minoxidil (topical fprmulation) [372]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Mirtazapine [373]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Misoprostol (gastrointestinal indication) [374]

Stanowisko CMDh - 06/06/2018   IAIN nr C.I.3 a)

Misoprostol (gynaecological indication - labour induction) [375]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Misoprostol (gynaecological indication) [376]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Misoprostol (gynaecological indication –termination of pregnancy) [377]

Stanowisko CMDh - 09/05/2018   IAIN nr C.I.3 a)
Mirtazapina [65] Pojedyncze sygnały   23/08/2020   IAIN nr C.I.z

Mizolastine [378]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)

Moclobemide [379]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Modafinil [380]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Mometasone+salicylic acid [381]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Morphine, 
morphine / cyclizine
[382]

Stanowisko CMDh - 10/10/2018 - IAIN nr C.I.3 a)
Moxifloxacin korekta Decyzji Komisji Europejskiej art. 31   12/03/2019 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Moxifloxacin (systemic use) [383]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Mycophenolic acid [384]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nabumetone [385]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

N-acetyl-aspartyl-glutamic acid [386]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Nadifloxacin [387]

Stanowisko CMDh

 

10/05/2017

 

IAIN nr C.I.3 a)

Nadroparin [388]

Stanowisko CMDh - 27/03/2019   IAIN nr C.I.3 a)

Nafarelin [389]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Naloxone [390]

PSUR worksharing - - - Bez konieczności złożenia zmian
Naproxen [391] Stanowisko CMDh - 08/08/2018   IAIN nr C.I.3 a)

Natalizumab [392]

Pojedyncze sygnały

-

06/08/2016

 

IAIN nr C.I.z

Natalizumab [225]

Pojedyncze sygnały

-

01/08/2015

 

IAIN nr C.I.z

Nebivolol [393]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nedocromil [394]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nefopam [395]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Nicardipine [396]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Nicardipine hydrochloride [397]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nifedipine [398]

Stanowisko CMDh

-

10/08/2016

 

IAIN nr C.I.3 a)

Nifuroxazide [399]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nilotynib [154]

Pojedyncze sygnały

-

07/05/2016

 

IAIN nr C.I.z

Nitrofurantoin, Nifurtoinol [400]

Stanowisko CMDh - 27/02/2019   IAIN nr C.I.3 a)

Nitrous oxide, nitrous oxide / oxygen [401]

Stanowisko CMDh - 06/06/2018   IAIN nr C.I.3 a)

Nilvadipine [402]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Nivolumab [345]

Pojedyncze sygnały

-

04/06/2017

 

IAIN nr C.I.z

Nivolumab [229]

Pojedyncze sygnały

-

06/05/2017

 

IAIN nr C.I.z

Niwolumab [296]

Pojedyncze sygnały   06/06/2020   IAIN nr C.I.z
Niwolumab [403] Pojedyncze sygnały   03/09/2023   IAIN nr C.I.z

Nivolumab [404]

Pojedyncze sygnały   10/05/2020   IAIN nr C.I.z

Nomegestrol [405]

Stanowisko CMDh - 30/01/2019   IAIN nr C.I.3 a)
Norfloxacin  Decyzja Komisji Europejskiej art. 31   12/03/2019

IAINnr C.I.1 a)/

IB nr C.I.1 b)

Nortriptyline [406]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Norepinefryna [109]

Pojedyncze sygnały  - 03.06.2018   IAIN nr C.I.z
Obinutuzumab [193] Pojedyncze sygnały    07.05.2022   IAIN nr C.I.z
Octenidine dihydrochloride, phenoxyethanol [407] Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Octreotide [408]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ofloxacin [409]

PSUR worksharing

-

-

 

 IB nr C.I.3 z)

ofloxacin Decyzja Komisji Europejskiej art. 31   12/03/2019

IAIN nr C.I.1 a)/

IB nr C.I.1 b)

Ofloxacin (systemic use) [410]

Stanowisko CMDh

-

30/03/2016

 

IAIN nr C.I.3 a)

Ofloxacin (topical use) [411]

Stanowisko CMDh

-

30/03/2016

 

IAIN nr C.I.3 a)

Olanzapine [68]

Pojedyncze sygnały

-

21/01/2017

 

IAIN nr C.I.z

Olanzapine [412]

Pojedyncze sygnały

-

10/07/2016

 

IAIN nr C.I.z

Olaparyb [413] Pojedyncze sygnały   31/10/2023   IAIN nr C.I.z

Oksybutynina [414]

Pojedyncze sygnały

-

08/04/2016

 

IAIN nr C.I.z

Ombitasvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Omega-3-acid-ethyl esters [415]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Omeprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Omeprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Omeprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Ondansetron [416]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Oxaliplatin [417]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Oxaliplatin [418]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Oxaliplatin [419]

Stanowisko CMDh   27/03/2019   IAIN nr C.I.3 a)

Oxatomide [420]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Oxcarbazepine [421]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Oxybutynin hydrochloride [422]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Oxytetracycline [423]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Ozenoxacin [424]

PSUR worksharing   Nie dotyczy   Bez konieczności złożenia zmian

Oxytocin [425]

Stanowisko CMDh - 04/07/2018   IAIN nr C.I.3 a)

Quinine [426]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)

Paclitaxel [427]

Stanowisko CMDh

-

18/12/2016

 

IAIN nr C.I.3 a)

Paclitaxel [428]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Pamidronate [429]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Pantoprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Pantoprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Pantoprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Paracetamol / Tramadol [430]

Stanowisko CMDh

-

14/07/2016

 

IAIN nr C.I.3 a)

Paracetamol/Tramadol [431]

PSUR worksharing

-

11/09/2016

 

IB nr C.I.3 z)

Paracetamol for infusion [432]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Paricalcitol [433]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Pariet (rabeprazole sodium) [434]

Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Paritaprevir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Paroxetine [435]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Paroxetine [436]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)
Paroksetyna [296] Pojedyncze sygnały   06/06/2020   IAIN nr C.I.z
Pefloxacin Decyzja Komisji Europejskiej art. 31   12/03/2019

IAIN nr C.I.1 a)/

IB nr C.I.1 b)

Peginterferon alfa-2a [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Peginterferon alfa-2b [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Peginterferon beta-1a [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Pembrolizumab [345]

Pojedyncze sygnały

-

04/06/2017

 

IAIN nr C.I.z

Pembrolizumab [47]

Pojedyncze sygnały - 11.08.2018   IAIN nr C.I.z
Pembrolizumab [134] Pojedyncze sygnały   26.12.2020   IAIN nr C.I.z
Pembrolizumab [122] Pojedyncze sygnały   06.03.2021   IAIN nr C.I.z

Pemetreksed  [186]

Pojedyncze sygnały - 05.04.2018   IAIN nr C.I.z

Penciclovir (topical use only) [437]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Perindopril [438]

Stanowisko CMDh

-

05/10/2016

 

IAIN nr C.I.3 a)

Permethrin [439] Stanowisko CMDh   08/08/2018   IAIN nr C.I.3 a)

Perphenazine [35]

Stanowisko CMDh

-

03/02/2016

 

IAIN nr C.I.3 a)

Phenindione [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Phenprocoumon [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Phenylephrine [440]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Pimecrolimus [441]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Piperacylina; piperacylina z tazobaktamem [144]

Pojedyncze sygnały   26.12.2021   IAIN nr C.I.z

Piretanide [442]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Pirfenidon [16] Pojedyncze sygnały   05.04.2024   IAIN nr C.I.z
Ponatynib [367] Pojedyncze sygnały - 30.11.2021   IAIN nr C.I.z

Pramiracetam [443]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Pramipeksol [359]

Pojedyncze sygnały

- 25/11/2017   IAIN nr C.I.z

Pravastatin [444]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Pravastatin sodium + buffered aspirin [445]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Praziquantel [446]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Prednisolone [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Prednisone [40]

Pojedyncze sygnały

-

07/10/2017

 

IAIN nr C.I.z

Prednizolon; prednizon (o działaniu ogólnoustrojowym) [447]

Pojedyncze sygnały   08/05/2021   IAIN nr C.I.z
Pregabalina [188] Pojedyncze sygnały   07.04.2022   IAIN nr C.I.z
Priorix (measles, mumps and rubella vaccine)  [448]
DE/W/0055/pdWS/005 [448]
Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Priorix (measles, mumps and rubella vaccine)
DE/W/0055/pdWS/003
[449]

Pediatryczny worksharing

Art. 46
Rozp. 1901/2006

Nie dotyczy   Bez konieczności złożenia zmian
Priorix (measles, mumps and rubella vaccine) [450]
DE/W/0055/pdWS/006 [450]
Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Procyanidolic oligomers [451]

PSUR worksharing - 13/08/2018   IB nr C.I.3 z)
Produkty zawierające makrogol (wszystkie masy cząsteczkowe i skojarzenia) do oczyszczania jelita [170] Pojedyncze sygnały   06/09/2020   IAIN nr C.I.z

Promestriene (cream and vaginal capsules) [452]

Stanowisko CMDh - 21/02/2018   IAIN nr C.I.3 a)

Propofol [58]

Pojedyncze sygnały

-

06/04/2017

 

IAIN nr C.I.z

Propofol [453]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Propofol [454]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)
Propofol [455] Pojedyncze sygnały   11/06/2023   IAIN nr C.I.z
Propofol [66] Pojedyncze sygnały   10.08.2024   IAIN nr C.I.z

Prulifloxacin [456]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Prulifloxacin [457]

Stanowisko CMDh   10/10/2018   IAIN nr C.I.3 a)
Prulifloxacin Decyzja Komisji Europejskiej art. 31   12/03/2019

IAIN nr C.I.1 a)/

IB nr C.I.1 b)

Quetiapine fumarate [458]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Rabbit anti-human thymocyte (powder for solution for infusion) [459]

Stanowisko CMDh

-

04/11/2015

 

IAIN nr C.I.3 a)

Rabbit anti-human thymocyte immunoglobulin [460]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Rabeprazole [6]

Pojedyncze sygnały

-

03/04/2017

 

IAIN nr C.I.z

Rabeprazole [165]

Pojedyncze sygnały

-

02/11/2016

 

IAIN nr C.I.z

Rabeprazol [155]

Pojedyncze sygnały

-

07/11/2015

 

IAIN nr C.I.z

Rabeprazole [461]

Stanowisko CMDh

-

04/10/2017

 

IAIN nr C.I.3 a)

Rabies vaccine [462]

Stanowisko CMDh

-

22/02/2017

 

IAIN nr C.I.3 a)

Ramipril [463]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ranitidine [464]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Recombinant human interferon gamma-1b [465]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Regorafenib [148] Pojedyncze sygnały   06/04/2023   IAIN nr C.I.z

Remifentanil [466]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Retinoids (acitretin, alitretinoin, isotretinoin) - doustne

Decyzja Komisji Europejskiej art. 31   22/06/2018 IB nr C.I.1 a) +
+ IAIN nr C.I.11 a)

Retinoids (acitretin,  bexarotene, tretinoin )- doustne

Decyzja Komisji Europejskiej art. 31   22/06/2018 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Retinoids (alitretinoin,  isotretinoin) -  doustne

Decyzja Komisji Europejskiej art. 31   22/06/2018 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Retinoids (adapalene, alitretinoin, isotretinoin, tazarotene, tretinoin) - stosowane miejscowo

Decyzja Komisji Europejskiej art. 31   22/06/2018 IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Riociguat [467]

Pojedyncze sygnały

-

03/08/2016

 

IAIN nr C.I.z

Rilmenidine [468]

Stanowisko CMDh

-

10/08/2016

 

IAIN nr C.I.3 a)

Risperidone [469]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ritonavir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Rizatriptan benzoate [470]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ropinirole [471]

Stanowisko CMDh

-

05/07/2017

 

IAIN nr C.I.3 a)

Ropivacaine [472]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Rosuvastatin [473]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)

Roxithromycin [474]

Stanowisko CMDh - 27/12/2017   IAIN nr C.I.3 a)
Rufloxacin  Decyzja Komisji Europejskiej art. 31   12/03/2019

IAINnr C.I.1 a)/

IB nr C.I.1 b)

Rupatadine [475]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Rupatadine fumarate [476]

PSUR worksharing

-

-

 

 IB nr C.I.3 z)

Rytonawir; lopinawir; rytonawir; ombitaswir; parytaprewir; rytonawir; lewotyroksyna [221]

Pojedyncze sygnały  - 05.05.2018   IAIN nr C.I.z

Sabrilex (vigabatrin) [477]

Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Saccharomyces boulardii [478]

Stanowisko CMDh - 24/01/2018   IAIN nr C.I.3 a)

Sativex (delta-9-tetrahydrocannabinol and cannabidiol) [479]

Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
02/11/2018* 
03/12/2018**
  IB nr C.I.3 z)
Sekukinumab [22] Pojedyncze sygnały   31/07/2021   IAIN nr C.I.z
Sertalina [65] Pojedyncze sygnały   23/08/2020   IAIN nr C.I.z
 

R worksharing

-

-

 

IB nr C.I.3 z)

Seretide Evohaler and related names (fluticasone propionate/salmeterol xinafoate) [480] Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
24/11/2018*
24/12/2018**
   IB nr C.I.3 z)

Simeprevir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Simvastatin [481]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Simvastatin [482]

Stanowisko CMDh   28/03/2018   IAIN nr C.I.3 a)

Sodium iodine (123I) [483]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Sodium valproate [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Sodium valproate Decyzja Komisji Europejskiej Art. 31 - 01/06/2018
IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub

IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)

Sodium iodide (131i) [484]

Stanowisko CMDh - 21/02/2018   IAIN nr C.I.3 a)

Sofosbuvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Sofosbuwir [149]

Pojedyncze sygnały

-

13/06/2015

 

IAIN nr C.I.z

Solifenacin [485]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Solifenacin/tamsulosin [486]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Sorafenib [193] Pojedyncze sygnały   07.05.2022   IAIN nr C.I.z
Spikevax [144] Pojedyncze sygnały   01.11.2021   IAIN nr C.I.z

Spironolactone [487]

Stanowisko CMDh

-

02/03/2016

 

IAIN nr C.I.3 a)

Standardised allergen extract from house dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farina) [488]

PSUR worksharing - 02/03/2018   IB nr C.I.3 z)

Strontium (89Sr) Chloride [489]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Sulfametoksazol, trimetoprym (kotrimoksazol) [22] Pojedyncze sygnały   31/07/2021   IAIN nr C.I.z

Sufentanil citrate [490]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Sulbactam [491]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Sulprostone [492]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Sulproston [493]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Szczepionka mRNA przeciw COVID-19 (ze zmodyfikowanymi nukleozydami) (Comirnaty) [22] Pojedyncze sygnały   14/06/2021   IAIN nr C.I.z
Szczepionka polisacharydowa przeciwko pneumokokom
(23 serotypy)
[494]
Pojedyncze sygnały   26/11/2022   IAIN nr C.I.z
Szczepionka przeciwko COVID-19 (ChAdOx1-S [rekombinowana]) (szczepionka AstraZeneca przeciwko COVID-19) [44] Pojedyncze sygnały   20/04/2021   IAIN nr C.I.z

Tapentadol [495]

Stanowisko CMDh   07/11/2018   IAIN nr C.I.3 a)

Tacrolimus [321]

Pojedyncze sygnały

-

26.02.2019

 

IAIN nr C.I.z

Technetium (99mTc) [496]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Technetium (99mTc) exametazime [497]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Technetium (Tc-99m) bicisate [498]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Technetium (99mtc) mebrofenin [499]

Stanowisko CMDh

-

02/11/2016

 

IAIN nr C.I.3 a)

Temozolomide [19]

Pojedyncze sygnały

-

02/07/2017

 

IAIN nr C.I.z

Tenoxicam [500]

Stanowisko CMDh

-

03/03/2016

 

IAIN nr C.I.3 a)

Teriflunomide [19]

Pojedyncze sygnały

-

02/07/2017

 

IAIN nr C.I.z

Teryflunomid [178]

Pojedyncze sygnały  

29.12.2018

 

IAIN nr C.I.z

Testosterone [501]

Stanowisko CMDh

Art. 31

20/02/2015

 

IB nr C.I.1 a) lub IB nr C.I.1 b)

Testosterone (all formulations apart from topical use and testosterone undecanoate injection) [502]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Testosterone (topical use) [503]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Testosterone undecanoate (injection) [504]

Stanowisko CMDh

-

28/12/2016

 

IAIN nr C.I.3 a)

Testosterone undecylate (injection) [505]

Stanowisko CMDh

-

04/11/2015

 

IAIN nr C.I.3 a)

Tetrabenazine [506]

Stanowisko CMDh

-

07/10/2015

 

IAIN nr C.I.3 a)

Thiocolchicoside [507]

Stanowisko CMDh

-

30/06/2016

 

IAIN nr C.I.3 a)

Thiopental [508]

Stanowisko CMDh

-

29/03/2017

 

IAIN nr C.I.3 a)

Tiagabine (hydrochloride) [509]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tianeptine [510]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tiapride [511]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tiazydy, leki moczopędne o strukturze zbliżonej do tiazydów i połączenia z nimi [296] Pojedyncze sygnały   06/06/2020   IAIN nr C.I.z

Tibolone [512]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tick-borne encephalitis vaccine (inactivated) [513]

PSUR worksharing

-

-

 

 IB nr C.I.3 z)

Ticlopidine [514]

Stanowisko CMDh

-

11/05/2016

 

IAIN nr C.I.3 a)

Tinidazole [515]

Pediatryczny worksharing Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Tioconazole [516]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tirofiban hydrochloride [517]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Ticarcillin and clavulanic acid [518]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Tixocortol, Tixocortol/Chlorhexidine [519]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tixocortol chlorhexidine gluconate / tixocortol pivalate [520] Stanowisko CMDh - 01/11/2017   IAIN nr C.I.3 a)

Tizanidine [521]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Tobi/Tobi Podhaler (tobramycin) 
UK/W/0089/pdWS/003
[522]

Pediatryczny worksharing Art. 46 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian
Tofacytynib [403] Pojedyncze sygnały   03/09/2023   IAIN nr C.I.z

Tolterodine [523]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Tozinameran (Szczepionka mRNA przeciwko COVID-19 – Comirnaty) [187] Pojedyncze sygnały   25/11/2022   IAIN nr C.I.z

Trabektedyna [127]

Pojedyncze sygnały

-

06/12/2015

 

IAIN nr C.I.z

Trabektedyna [149]

Pojedyncze sygnały

-

13/07/2015

 

IAIN nr C.I.z

Tramadol [524]

Stanowisko CMDh - 11/05/2018   IAIN nr C.I.3 a)
Tramadol; tramadol, deksketoprofen; tramadol, paracetamol [22] Pojedyncze sygnały   31/07/2021   IAIN nr C.I.z

Trandolapril + Verapamil [525]

Stanowisko CMDh

-

02/03/2016

 

IAIN nr C.I.3 a)

Trandolapril + Verapamil [526]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Treprostinil [527]

Stanowisko CMDh

-

10/05/2017

 

IAIN nr C.I.3 a)

Treprostinil [528]

Stanowisko CMDh - 10/10/2018   IAIN nr C.I.3 a)

Triamcinolone acetonide [529]

Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
03/12/2018* 
31/12/2018**
  IB nr C.I.3 z)

Triamcinolone (intraocular formulations) [530]

Stanowisko CMDh

-

24/02/2017

 

IAIN nr C.I.3 a)

Trileptal (Oxcarbazepine) [531]

Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
28/12/2018* 
27/01/2019**
  IB nr C.I.3 z)

Trimetazidine [532]

Stanowisko CMDh

-

05/07/2017

 

IAIN nr C.I.3 a)

Tropicamide [533] Pediatryczny worksharing
Art. 45 
Rozp. 1901/2006
Nie dotyczy   Bez konieczności złożenia zmian

Tybolon [62]

Pojedyncze sygnały

-

06/04/2016

 

IAIN nr C.I.z

Tygecyklina [18]

Pojedyncze sygnały

-

11/06/2016

 

IAIN nr C.I.z

Typhim Vi (Salmonella Typhimurium) [534]

Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
02/11/2018* 
03/12/2018**
  IB nr C.I.3 z)
Warfaryna [144] Pojedyncze sygnały   26.12.2021   IAIN nr C.I.z

 Valaciclovir [535]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Valproate [536]

Stanowisko CMDh

Art. 31

-

 

  IB nr C.I.3 z)

Valproate Decyzja Komisji Europejskiej Art. 31 - 01/06/2018
IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub
IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)

Valproate bismuth [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Valproate magnesium [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Valproate pivoxil [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Valproate semisodium [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Valproate semisodium Decyzja Komisji Europejskiej Art. 31 01/06/2018  
IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub

IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)

Valproic acid [99]

Stanowisko CMDh

-

06/01/2016

 

IAIN nr C.I.3 a)

Valproic acid Decyzja Komisji Europejskiej Art. 31 - 01/06/2018
IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub

IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)
Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium [537] Stanowisko CMDh -
02/01/2019
  IAIN nr C.I.3 a)

Valpromide [99]

Stanowisko CMDh

-

   06/01/2016

 

IAIN nr C.I.3 a)

Valpromide Decyzja Komisji Europejskiej Art. 31 - 01/06/2018
IB nr C.I.1 a) +
+ IAIN nr C.I.11 a) lub

IB nr C.I.1 b) +
+ IAIN nr C.I.11 a)

Valsartan [538]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Vancomycin

Decyzja Komisji Europejskiej art. 31 - 22.09.2017 r. IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Vancomycin

korekta Decyzji Komisji Europejskiej art. 31 - 17.11.2017 r. IAIN nr C.I.1 a)/
IB nr C.I.1 b)

Varicella Vaccine (live) [539]

PSUR worksharing

-

  -

 

IB nr C.I.3 z)

Vaxzevria [540] Pojedyncze sygnały   13.11.2021   IAIN nr C.I.z

Vecuronium bromide [541]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Velpatasvir [14]

Pojedyncze sygnały

-

26/11/2016

 

IAIN nr C.I.z

Venlafaxine [542]

PSUR worksharing - 18/02/2018   IB nr C.I.3 z)

Vildagliptin [6]

Pojedyncze sygnały

-

03/03/2017

 

IAIN nr C.I.z

Warfarin [392]

Pojedyncze sygnały

-

06/09/2016

 

IAIN nr C.I.z

Wortioksetyna [34]

Pojedyncze sygnały - 07.07.2018   IAIN nr C.I.z
Worykonazol; flukloksacylina [455] Pojedyncze sygnały   11/06/2023   IAIN nr C.I.z

Zafirlukast [543]

PSUR worksharing

-

-

 

IB nr C.I.3 z)

Zithromax (azithromycin (dehydrate)) [544] Pediatryczny worksharing
Art. 46 
Rozp. 1901/2006
15/03/2019*
14/04/2019**
  IB nr C.I.3 z)

 Zolmitriptan [545]

PSUR worksharing

-

-

 

   IB nr C.I.3 z)

Donepezil [546]

Pojedyncze sygnały

  02/10/2021   IAIN nr C.I.z
Inhibitory immunologicznych punktów kontrolnych: atezolizumab, awelumab, cemiplimab, durwalumab, ipilimumab, pembrolizumab, niwolumab [546] Pojedyncze sygnały   02/10/2021   IAIN nr C.I.z
Oktreotyd [546] Pojedyncze sygnały   02/10/2021   IAIN nr C.I.z
Szczepionka przeciwko COVID-19 (ChAdOx1-S [rekombinowana]) — Vaxzevria [547] Pojedyncze sygnały   29/06/2021   IAIN nr C.I.z
Ceftriakson [548] Pojedyncze sygnały   05/09/2021   IAIN nr C.I.z
Tofacytynib [548] Pojedyncze sygnały   05/09/2021   IAIN nr C.I.z
Olmesartan; olmesartan, amlodypina; olmesartan, hydrochlorotiazyd; olmesartan medoksomil, bezylan amlodypiny, hydrochlorotiazyd [549] Pojedyncze sygnały   06/03/2022   IAIN nr C.I.z

 * - termin złożenia zmiany dla podmiotu odpowiedzialnego, który składał dane oceniane w ramach procedury worksharing

** - termin złożenia zmiany dla pozostałych podmiotów odpowiedzialnych produktów leczniczych zawierających tę samą substancję czynną i postać farmaceutyczną


Źródłowy URL: https://archiwum.urpl.gov.pl/pl/produkty-lecznicze/zalecenia-dla-podmiot%C3%B3w-odpowiedzialnych

Odnośniki
[1] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/17-alpha-oestradiol_topical_SAR_2017_02.pdf
[2] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214315.pdf
[3] https://www.ema.europa.eu/documents/psusa-conclusions/5-fluorouracil-iv-application-cmdh-scientific-conclusions-grounds-variation-amendments-product/00000007/201712_pl.pdf
[4] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Technetium_99mTc_macrosalb_SAR_2014_04.pdf
[5] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020_pl.pdf
[6] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/01/WC500219294.pdf
[7] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/10/WC500237199.pdf
[8] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac_pl.pdf
[9] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Acetylsalicylic_acid_Art.45_PAR_2018_04.pdf
[10] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/08/WC500211852.pdf
[11] https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_pl.pdf
[12] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021_pl.pdf
[13] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/07/WC500251941.pdf
[14] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/09/WC500213124.pdf
[15] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Salmeterol_xinafoate_fluticasone_propionate_2018_09.pdf
[16] https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_pl.pdf
[17] https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_pl.pdf
[18] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/04/WC500204647.pdf
[19] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/05/WC500226577.pdf
[20] https://www.ema.europa.eu/documents/psusa-conclusions/aldesleukin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00000076/201712_pl.pdf
[21] https://www.ema.europa.eu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018_pl.pdf
[22] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac_pl.pdf
[23] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_pl.pdf
[24] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237281.pdf
[25] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/11/WC500216582.pdf
[26] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500249950.pdf
[27] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245238.pdf
[28] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214408.pdf
[29] https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_pl.pdf
[30] https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_pl.pdf
[31] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214409.pdf
[32] https://www.ema.europa.eu/documents/psusa-conclusions/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00000126/201801_pl.pdf
[33] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214414.pdf
[34] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/05/WC500248801.pdf
[35] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214412.pdf
[36] https://www.ema.europa.eu/documents/psusa-conclusions/amitriptyline-amitriptyline/amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product/00010374/201801_pl.pdf
[37] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238792.pdf
[38] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Amlodipine_Atorvastatine_SAR_2016_05.pdf
[39] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214415.pdf
[40] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/08/WC500233098.pdf
[41] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Amphotericin_B_Art.45_PAR_2018_04.pdf
[42] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214457.pdf
[43] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2015/11/WC500196278.pdf
[44] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_pl.pdf
[45] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_en.pdf
[46] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215087.pdf
[47] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2018/06/WC500250488.pdf
[48] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214462.pdf
[49] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214460.pdf
[50] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214464.pdf
[51] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Asmanex_Twisthaler_02_2018_Art._46_PAR.pdf
[52] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214467.pdf
[53] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214469.pdf
[54] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Atorvastatin_SAR_2017_08.pdf
[55] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500253901.pdf
[56] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Atovaquone_and_proguanil_hydrochloride_2018_09.pdf
[57] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Atracurium_SmAR_10_2017.pdf
[58] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/02/WC500220973.pdf
[59] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023_pl.pdf
[60] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac_pl.pdf
[61] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/02/WC500244579.pdf
[62] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/01/WC500199438.pdf
[63] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237770.pdf
[64] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/07/WC500231714.pdf
[65] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_pl.pdf
[66] https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_pl.pdf
[67] https://www.ema.europa.eu/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-grounds-variation-amendments-product/00000304/201803_pl.pdf
[68] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/11/WC500216685.pdf
[69] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214625.pdf
[70] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214627.pdf
[71] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/11/WC500215651.pdf
[72] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237255.pdf
[73] https://www.ema.europa.eu/documents/psusa-conclusions/bendroflumethiazide-bendroflumethiazide/potassium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information_pl.pdf
[74] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214629.pdf
[75] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Berinert_Art.46_12_2018.pdf
[76] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/11/WC500216759.pdf
[77] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238822.pdf
[78] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214635.pdf
[79] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245121.pdf
[80] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac_pl.pdf
[81] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214891.pdf
[82] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215206.pdf
[83] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215393.pdf
[84] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/05/WC500228459.pdf
[85] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Bromazepam_SAR_10_2017.pdf
[86] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Brotizolam_SAR_2014_09.pdf
[87] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223322.pdf
[88] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Budesonide_SAR_2016_08.pdf
[89] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/budesonide_formoterol.pdf
[90] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Buflomedil_hydrochloride_PSUR_SAR.pdf
[91] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Bumetanide_2018_09.pdf
[92] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/PSUR_WS_buprenorphine_2016_12.pdf
[93] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/11/WC500216617.pdf
[94] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Cabergoline_PSUR_SAR_2016_02.pdf
[95] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/07/WC500251988.pdf
[96] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214649.pdf
[97] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/calcium_carbonate_colecalciferol.pdf
[98] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Calcium_chloride_dihydrate_etc_SaR_2018_06.pdf
[99] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214325.pdf
[100] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Candesartan_SAR_2014_09.pdf
[101] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245041.pdf
[102] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/01/WC500220336.pdf
[103] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/captopril__hydrochlorothiazide_PSUR_SAR.pdf
[104] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/11/WC500216557.pdf
[105] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/08/WC500233059.pdf
[106] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214655.pdf
[107] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Carteolol_SAR_2015_02.pdf
[108] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500248033.pdf
[109] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2018/04/WC500246649.pdf
[110] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/cefepime_SAR_2015_10.pdf
[111] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020_pl.pdf
[112] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215422.pdf
[113] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215180.pdf
[114] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Cefotaxime_SAR_2014_01.pdf
[115] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242436.pdf
[116] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ceftazidime_2015_01.pdf
[117] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Certican_02_2018_Art._46_PdAR.pdf
[118] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Cetirizine_SAR_2014_02.pdf
[119] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2017/06/WC500230337.pdf
[120] https://www.ema.europa.eu/documents/psusa-conclusions/cisplatin-cmdh-scientific-conclusions-amendments-product-information-implementation-timetable-psusa/00000778/201712_pl.pdf
[121] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/12/WC500240068.pdf
[122] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020_pl.pdf
[123] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214664.pdf
[124] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/07/WC500230459.pdf
[125] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/PSUR_WS_chlorpromazine_2016_12.pdf
[126] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/chlorprothixene_hydrochloride_SAR_2014_06.pdf
[127] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2015/10/WC500195097.pdf
[128] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ciclopirox__shampoo_only__SmAR_2018_04.pdf
[129] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ciclosporin_SAR_2013_11.pdf
[130] https://www.ema.europa.eu/documents/psusa/cilazapril-cilazapril/hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information_pl.pdf
[131] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214670.pdf
[132] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ciprofloxacin_SAR_2015_09.pdf
[133] https://www.ema.europa.eu/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product/00000775/201801_pl.pdf
[134] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october_pl.pdf
[135] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ciprofloxacin_dexamethason_SAR_2015_11.pdf
[136] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Clarithromycin_SAR_2016_05.pdf
[137] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/02/WC500243557.pdf
[138] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Clebopride_PSUR_SAR.pdf
[139] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Clevidipine_Summary_AR_2015_05.pdf
[140] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Clodronate_SAR_2014_04.pdf
[141] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Clostridium_botulinum_neurotoxin_type_A_haemagglutinin_complex_PSUR_SAR.pdf
[142] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Clostridium_botulinum_toxin_05_2018.pdf
[143] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Codeine_containing_medicinal_products_for_the_treatment_of_cough_and_cold_in_paediatric_patients/human_referral_prac_000039.jsp&mid=WC0b01ac05805c516f
[144] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september_pl.pdf
[145] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214383.pdf
[146] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214385.pdf
[147] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/cyproterone_acetate___ethinylestradiol_SAR_2015_10.pdf
[148] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac_pl.pdf
[149] http://www.ema.europa.eu/docs/pl_PL/document_library/PRAC_recommendation_on_signal/2015/05/WC500186846.pdf
[150] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Danaparoid_SAR_2014_10.pdf
[151] https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_pl.pdf
[152] https://www.ema.europa.eu/documents/psusa-conclusions/dapoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable_pl.pdf
[153] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214390.pdf
[154] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/03/WC500202894.pdf
[155] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2015/08/WC500191719.pdf
[156] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214392.pdf
[157] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500247840.pdf
[158] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Deoxicholic_acid_SAR_2017_11.pdf
[159] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500253939.pdf
[160] https://www.ema.europa.eu/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information/00010525/201804_pl.pdf
[161] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Deoxyribonuclease_human_dirnase_alpha_SAR_2016_03.pdf
[162] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/desogestrel_SAR_2014_07.pdf
[163] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/11/WC500217416.pdf
[164] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500250513.pdf
[165] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/08/WC500211453.pdf
[166] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500237938.pdf
[167] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Dexibuprofen_Summary_AR_2015_05.pdf
[168] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Dexketoprofen_SAR_2013_11.pdf
[169] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214438.pdf
[170] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_pl.pdf
[171] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237355.pdf
[172] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500248111.pdf
[173] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214441.pdf
[174] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Didanosine_PSUR_SAR_2015_12.pdf
[175] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Dinoprostone_2014_11.pdf
[176] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Diovan_Angiosan_Valsartan_Novartis__valsartan_-_Art._46_PAR.pdf
[177] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Valsartan_Art_46_PAR_12_2017.pdf
[178] https://www.ema.europa.eu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_pl.pdf
[179] https://archiwum.urpl.gov.pl/sites/default/files/zalaczniki/WC500234300.pdf
[180] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/12/WC500218958.pdf
[181] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/dorzolamide__timolol.pdf
[182] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214761.pdf
[183] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/doxylamine_PSUR_SAR.pdf
[184] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Doxycycline_02_2018_Art._45_PAR_.pdf
[185] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Drospirenone__ethinylestradiol_SAR_2014_10.pdf
[186] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/02/WC500243151.pdf
[187] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022_pl.pdf
[188] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022_pl.pdf
[189] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/dutasteride_SAR_2014_06.pdf
[190] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ebastine_SAR_2015_06.pdf
[191] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Econazole-econazole_combinations_SAR_2013_11.pdf
[192] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Enalapril_SAR_2014_02.pdf
[193] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022_pl.pdf
[194] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500253968.pdf
[195] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/epinastine_hydrochloride_SAR_2014_07.pdf
[196] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Epirubicin_PSUR_SAR_2015_12.pdf
[197] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242142.pdf
[198] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Eprosartan_hydrochlorothiazide_November_2017.pdf
[199] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Eprosartan_November_2017.pdf
[200] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021_pl.pdf
[201] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Erythromycin_2018_09.pdf
[202] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/estradiol_dienogest_SAR_2014_05.pdf
[203] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Estradiol_norethisterone_SAR_2014_09.pdf
[204] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ethinylestradiol_dienogest.pdf
[205] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ethinylestradiol_levonorgestrel_SAR_2016_04.pdf
[206] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238503.pdf
[207] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Etomidate_PSUR_SmAR_July_2017.pdf
[208] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/07/WC500251918.pdf
[209] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214647.pdf
[210] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ezetimibe_SAR_2015_06.pdf
[211] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/05/WC500248462.pdf
[212] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ezetimibe__simvastatin_SAR_01_2018.pdf
[213] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214674.pdf
[214] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/07/WC500251965.pdf
[215] https://archiwum.urpl.gov.pl/sites/default/files/zalaczniki/WC500234898.pdf
[216] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/felodipine___ramipril_SAR_2014_06.pdf
[217] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/fenoterol_hydrobromide-ipratropium_bromide_SAR_2014_06.pdf
[218] https://www.ema.europa.eu/documents/psusa/fenspiride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00001368/201804_pl.pdf
[219] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/fentanyl_SAR_2015_10.pdf
[220] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ferumoxsil_SAR_2014_05.pdf
[221] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2018/03/WC500244960.pdf
[222] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/finasteride_SAR_2015_09.pdf
[223] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/05/WC500228684.pdf
[224] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500250190.pdf
[225] http://www.ema.europa.eu/docs/pl_PL/document_library/PRAC_recommendation_on_signal/2015/06/WC500187420.pdf
[226] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Benzylnicotine_comb_SAR_2014_01.pdf
[227] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238277.pdf
[228] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Fluconazole_Updated_SAR_2016_01.pdf
[229] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/03/WC500222392.pdf
[230] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Flumazenil_SAR_2014_04.pdf
[231] https://www.ema.europa.eu/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-grounds-variation-amendments-product-information/00010002/201803_pl.pdf
[232] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Fluoxetine_SAR_2015_06.pdf
[233] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/fluticasone.pdf
[234] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500240862.pdf
[235] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Fluvoxamine_2018_03.pdf
[236] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/07/WC500251381.pdf
[237] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245044.pdf
[238] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Folinic_acid__di_sodium_folinate_calcium_folinate_PSUR_SAR_2015_12.pdf
[239] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/formoterol_PSUR_SAR.pdf
[240] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214614.pdf
[241] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214612.pdf
[242] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Fusidic_acid_SAR_2014_10.pdf
[243] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/11/WC500217363.pdf
[244] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/gabapentin_SAR_2015_10.pdf
[245] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/07/WC500230379.pdf
[246] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214692.pdf
[247] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214694.pdf
[248] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Gadodiamid_SAR_2014_02.pdf
[249] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214696.pdf
[250] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Gadopentetic_acid_PSUR_SAR_2015_12.pdf
[251] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214698.pdf
[252] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214700.pdf
[253] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214687.pdf
[254] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Gadoteridol_SAR_2014_02.pdf
[255] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214689.pdf
[256] https://www.ema.europa.eu/documents/psusa/gemcitabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00001519/201801_pl.pdf
[257] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242435.pdf
[258] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Genotropin__somatropin__Art.46_PAR_2018_10.pdf
[259] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/03/WC500203290.pdf
[260] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Glatiramer_SAR_2014_01.pdf
[261] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214295.pdf
[262] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242197.pdf
[263] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214298.pdf
[264] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/07/WC500209923.pdf
[265] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214300.pdf
[266] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/12/WC500219037.pdf
[267] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500239218.pdf
[268] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Havrix_Junior_720_Art._46_PAR_2018_10.pdf
[269] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Human_coagulation_factor_VII_SAR_2014_10.pdf
[270] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/human_coagulation_factor_VIII_SAR_2016_10.pdf
[271] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/human_coagulation_factor_VIII_inhibitor_SAR_2015_11.pdf
[272] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Human_fibirinogen_SmAR_09_2018.pdf
[273] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Humatrope_somatropin_Art.46_PAR_002_2018_04.pdf
[274] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Humatrope_somatropin_Art.46_PAR_003_2018_04.pdf
[275] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Humatrope_somatropin_Art.46_PAR_004_2018_04.pdf
[276] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Humatrope_somatropin_Art.46_PAR_005_2018_04.pdf
[277] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Priorix_Art.46_PAR_2018_04.pdf
[278] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214341.pdf
[279] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215354.pdf
[280] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Hydroquinidine_PSUR_SAR.pdf
[281] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Hydroxyzine/human_referral_prac_000043.jsp&mid=WC0b01ac05805c516f
[282] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500254741.pdf
[283] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Ibuprofen_and_dexibuprofen_containing_medicines/human_referral_prac_000045.jsp&mid=WC0b01ac05805c516f
[284] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500240798.pdf
[285] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500246743.pdf
[286] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ibutilide_SAR_2014_02.pdf
[287] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/idarubicin.pdf
[288] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Imipenem_cilastatin_PSUR_SAR_2015_12.pdf
[289] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2018/08/WC500253111.pdf
[290] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Inactivated_Hepatitis_A_virus_antigen_Art45_PAR_12_2017.pdf
[291] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/influenza_vaccine__split_virion_inactivated__SAR_2015_10.pdf
[292] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Indium_SAR_2014_01.pdf
[293] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Indobufen_Summary_AR_2015_05.pdf
[294] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Infanrix_-_2018_07_-_45PaedAR_.pdf
[295] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214398.pdf
[296] https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_pl.pdf
[297] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_pl.pdf
[298] http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation_on_signal/2017/05/WC500227846.pdf
[299] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2018/01/WC500240924.pdf
[300] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Interferon_alfa_2a_SAR_2014_12.pdf
[301] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500246675.pdf
[302] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/iobitridol_SAR_2015_10.pdf
[303] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214421.pdf
[304] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ipratropium.pdf
[305] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ipratropium_salbutamol.pdf
[306] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500239348.pdf
[307] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Irinotecan_SAR_2017_10.pdf
[308] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245046.pdf
[309] https://www.ema.europa.eu/documents/psusa-conclusions/iron-parenteral-preparations-cmdh-scientific-conclusions-grounds-variation-amendments-product/00010236/201801_pl.pdf
[310] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214424.pdf
[311] https://archiwum.urpl.gov.pl/sites/default/files/zalaczniki/WC500234071.pdf
[312] https://www.ema.europa.eu/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product/00010488/201805_pl.pdf
[313] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Isradipine_SAR_2016_03.pdf
[314] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ivermectin_SAR_2015_11.pdf
[315] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500241861.pdf
[316] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/02/WC500220684.pdf
[317] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Ketamine_Art_45_PAR_2017_10.pdf
[318] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ketoprofen__except_topical_use__SAR_2014_03.pdf
[319] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ketoprofen__topical_use_only__SAR_2015_10.pdf
[320] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022_pl.pdf
[321] https://www.ema.europa.eu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018_pl.pdf
[322] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Labetalol_PSUR_SAR_2015_12.pdf
[323] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Lamotrigine_SAR_2014_04.pdf
[324] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/09/WC500255159.pdf
[325] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Landiolol_SAR_12_2017.pdf
[326] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242012.pdf
[327] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Latanoprost_timolol_Summary_AR_2015_05.pdf
[328] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/lenograstim_SAR_2015_10.pdf
[329] https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_en.pdf
[330] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/08/WC500233852.pdf
[331] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/07/WC500232076.pdf
[332] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500250001.pdf
[333] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/10/WC500215146.pdf
[334] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237226.pdf
[335] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/levobupivacaine.pdf
[336] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Levocetirizine_PSUR_SAR_2017_05.pdf
[337] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500248145.pdf
[338] https://www.ema.europa.eu/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information/00001856/201712_pl.pdf
[339] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/levosimendan_SAR_2014_07.pdf
[340] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Lidocaine_Hydrochloride_Art._46_PAR_01_2018_.pdf
[341] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/lomustine_SAR_2014_06.pdf
[342] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Loratadine_SAR_2014_12.pdf
[343] https://www.ema.europa.eu/documents/psusa/lorazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00001909/201801_pl.pdf
[344] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214524.pdf
[345] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/04/WC500225202.pdf
[346] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Losartan_hydrochlorothiazide_SAR_2014_02.pdf
[347] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Lovastatin_SAR_2014_04.pdf
[348] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Lubiprostone_Summary_AR_2015_05.pdf
[349] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Lymecycline_Art_45_PAR_01_2018.pdf
[350] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/macrogol_4000_PSUR_SAR.pdf
[351] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Macrogol_4000_and_combinations_PSUR_SAR_2015_12.pdf
[352] https://archiwum.urpl.gov.pl/sites/default/files/zalaczniki/WC500234327.pdf
[353] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Mefloquine_SAR_2016_01.pdf
[354] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500240837.pdf
[355] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/05/WC500226851.pdf
[356] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Mepivacaine_PSUR_SAR_2016_02.pdf
[357] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214534.pdf
[358] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Mesalazine_PSUR_SAR_2015_12.pdf
[359] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2017/09/WC500235456.pdf
[360] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/05/WC500248916.pdf
[361] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245168.pdf
[362] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245013.pdf
[363] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Methylphenidate_hydrochloride_SAR_2014_09.pdf
[364] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214544.pdf
[365] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Medicinal_products_containing_lactose_of_bovine_origin_for_IV/human_referral_prac_000063.jsp&mid=WC0b01ac05805c516f
[366] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214547.pdf
[367] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september_pl.pdf
[368] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214549.pdf
[369] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245306.pdf
[370] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/milnacipran_SAR_2015_10.pdf
[371] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214561.pdf
[372] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214565.pdf
[373] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/mirtazapine.pdf
[374] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500247181.pdf
[375] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223583.pdf
[376] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/misoprostol_gynaecological_indication_PSUR_SAR.pdf
[377] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245490.pdf
[378] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/09/WC500254804.pdf
[379] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Moclobemide_SAR_2014_04.pdf
[380] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/modafinil_PSUR_SAR.pdf
[381] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/mometasone_salicylic_acid_SAR_2014_07.pdf
[382] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500252934.pdf
[383] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500222940.pdf
[384] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/mycophenolic_acid_SAR_2014_06.pdf
[385] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/nabumetone.pdf
[386] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/N-acetyl-aspartyl-glutamic_acid_2018_09.pdf
[387] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223103.pdf
[388] https://www.ema.europa.eu/documents/psusa/nadroparin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00002104/201803_pl.pdf
[389] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/nafarelin_PSUR_SAR.pdf
[390] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Naloxone_2018_03.pdf
[391] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500250085.pdf
[392] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/06/WC500208118.pdf
[393] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Nebivolol_SAR_2014_02.pdf
[394] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Nedocromil_PSUR_SAR_2015_12.pdf
[395] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223345.pdf
[396] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500222861.pdf
[397] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/nicardipine_SAR_2014_07.pdf
[398] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214576.pdf
[399] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/nifuroxazide_PSUR_SAR.pdf
[400] https://www.ema.europa.eu/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-grounds-variation-amendments-product/00002174/201802_pl.pdf
[401] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500247125.pdf
[402] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Nilvadipine_SAR_2014_01.pdf
[403] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac_pl.pdf
[404] https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-february-2020-prac-meeting_en.pdf
[405] https://www.ema.europa.eu/documents/psusa/nomegestrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00002181/201801_pl.pdf
[406] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Nortriptyline_SAR_2014_03.pdf
[407] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237399.pdf
[408] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/octreotide_PSUR_SAR.pdf
[409] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ofloxacin_SAR_2014_10.pdf
[410] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214585.pdf
[411] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214587.pdf
[412] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/05/WC500206033.pdf
[413] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac_pl.pdf
[414] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/02/WC500201457.pdf
[415] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238410.pdf
[416] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214592.pdf
[417] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214594.pdf
[418] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/oxaliplatin_PSUR_SAR.pdf
[419] https://www.ema.europa.eu/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00002229/201804_pl.pdf
[420] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Oxatomide_SAR_2014_10.pdf
[421] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/oxcarbazepine_SAR_2015_09.pdf
[422] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Oxybutinin_2015_01.pdf
[423] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Oxytetracycline_2018_09.pdf
[424] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ozenoxacin_PSUR_WS_-_SAR_2018_07.pdf
[425] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/04/WC500248171.pdf
[426] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500237535.pdf
[427] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500215208.pdf
[428] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Paclitaxel_SAR_2014_10.pdf
[429] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214596.pdf
[430] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214291.pdf
[431] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Paracetamol_Tramadol_SAR_2016_05.pdf
[432] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Paracetamol_for_infusion_PSUR_SAR_2015_12.pdf
[433] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Paricalcitol_SAR_2014_12.pdf
[434] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Rabeprazole_2018_03_Art.46.pdf
[435] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/paroxetine_SAR_2014_05.pdf
[436] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/09/WC500255200.pdf
[437] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Penciclovir_topical_use_only_SAR_2014_04.pdf
[438] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214330.pdf
[439] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/06/WC500250225.pdf
[440] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214371.pdf
[441] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/pimecrolimus_SAR_2015_10.pdf
[442] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Piretanide_PSUR_SAR_2016_02.pdf
[443] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214417.pdf
[444] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/pravastatin_SAR_2015_11.pdf
[445] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Pravastatin-aspirin_SAR_2016_09.pdf
[446] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Praziquantel_SAR_2016_01.pdf
[447] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021_pl.pdf
[448] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Priorix_2018_09.pdf
[449] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Priorix_Art.46_PAR_11_2017.pdf
[450] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Priorix_Art._46_PAR_2019_01.pdf
[451] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Procyanidolic_oligomers_SmAR_2018_04_.pdf
[452] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/12/WC500240715.pdf
[453] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Propofol_SAR_2015_06.pdf
[454] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/09/WC500255338.pdf
[455] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_pl.pdf
[456] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214426.pdf
[457] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500253810.pdf
[458] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Quetiapine_fumarate_PSUR_SAR_2015_12_rev.1.pdf
[459] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214450.pdf
[460] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Rabbit_anti-human_thymocyte_immunoglobulin_SAR_2014_03.pdf
[461] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/07/WC500232371.pdf
[462] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/12/WC500218339.pdf
[463] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ramipril_PSUR_SAR_2016_02.pdf
[464] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Ranitidine_SAR_2014_12.pdf
[465] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Interferon_gamma-1b_SAR_2014_04.pdf
[466] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Remifentanil_SmAR_July_2017.pdf
[467] http://www.ema.europa.eu/docs/pl_PL/document_library/Other/2016/07/WC500209641.pdf
[468] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214480.pdf
[469] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Risperidone_PSUR_SAR_2016_02.pdf
[470] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/rizatriptan_benzoate_SAR_2014_06.pdf
[471] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/05/WC500226615.pdf
[472] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/ropivacaine_SAR_2015_09.pdf
[473] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500254712.pdf
[474] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/10/WC500236919.pdf
[475] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/rupatadine.pdf
[476] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Rupatadine_as_fumarate_PSUR_SAR.pdf
[477] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Sabrilex_2019_08.pdf
[478] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/11/WC500238766.pdf
[479] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Sativex_2018_09.pdf
[480] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Seretide_Evohaler_Art.46_PAR_2018_10.pdf
[481] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Simvastatin_PSUR_SAR.pdf
[482] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500242167.pdf
[483] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Sodium_Iodide__123I__SAR_2014_03.pdf
[484] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/01/WC500240900.pdf
[485] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/solifenacin_PSUR_SAR.pdf
[486] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Solifenacin-tamsulosin_Summary_AR_2015_05.pdf
[487] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214556.pdf
[488] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Standardised_allergen_extract_from_house_dust_mites__Dermatophagoides_pteronyssinus_and_Dermatophagoides_farina_Acarizax__Amitend__Aitaro_November_2017.pdf
[489] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Strontium__89Sr__chloride_PSUR_SAR_2015_12.pdf
[490] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/sufentanil_citrate_SAR_2014_05.pdf
[491] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/sulbactam_PSUR_SAR.pdf
[492] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223136.pdf
[493] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/sulproston_PSUR_SAR.pdf
[494] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september_pl.pdf
[495] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/09/WC500254930.pdf
[496] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Technetium_albumin_nanocolloid_SAR_2014_01.pdf
[497] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Technetium__99mTc__exametazime_SAR_2014_03.pdf
[498] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Technetium_Tc-99m_bicisate_2014_11.pdf
[499] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214737.pdf
[500] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214740.pdf
[501] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f
[502] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/11/WC500215720.pdf
[503] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/11/WC500215589.pdf
[504] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/11/WC500215721.pdf
[505] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214745.pdf
[506] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214751.pdf
[507] http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/05/WC500206912.pdf
[508] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/01/WC500220338.pdf
[509] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tiagabine_hydrochloride_PSUR_SAR_2015_12.pdf
[510] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tianeptine_Summary_AR_2015_05.pdf
[511] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/tiapride_SAR_2015_11.pdf
[512] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tibolone_SAR_2014_10.pdf
[513] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tick-borne_encephalitis_vaccine_inactivated_SAR_2014_12.pdf
[514] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214717.pdf
[515] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Tinidazole_-_Art._45_PAR__2018_11.pdf
[516] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tioconazol_SAR_2014_12.pdf
[517] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/tirofiban_hydrochlorid_SAR_2014_07.pdf
[518] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Clavulanic_acid_and_ticarcillin_2018_09.pdf
[519] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tixocortol_Tixocortol_chlorhexidine_PSUR_SAR_2015_12.pdf
[520] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/08/WC500233886.pdf
[521] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214301.pdf
[522] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/TOBI_02_2018_Art.46_PAR.pdf
[523] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Tolterodine_SAR_2014_10.pdf
[524] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/03/WC500245268.pdf
[525] http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/10/WC500214305.pdf
[526] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Trandolapril_verapamil_SAR_2014_04.pdf
[527] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223135.pdf
[528] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2018/08/WC500252906.pdf
[529] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Triamcinolone_acetonide_2018_09.pdf
[530] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2016/12/WC500218957.pdf
[531] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Trileptal_-_Art._46_PAR__2018_11.pdf
[532] http://www.ema.europa.eu/docs/pl_PL/document_library/Periodic_safety_update_single_assessment/2017/05/WC500226850.pdf
[533] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Tropicamide_Art_45_PAR_2019_01.pdf
[534] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Typhim_Vi_2018_09.pdf
[535] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Valaciclovir_SAR_2016_01.pdf
[536] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substances/human_referral_prac_000032.jsp&mid=WC0b01ac05805c516f
[537] https://www.ema.europa.eu/documents/psusa-conclusions/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific/00003090/201801_pl.pdf
[538] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/valsartan_PSUR_SAR.pdf
[539] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Varicella_vaccine__live__SAR_2017_03.pdf
[540] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac_pl.pdf
[541] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/vecuronium_bromide_PSUR_SAR.pdf
[542] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Venlafaxine_SAR_2017_11.pdf
[543] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/Zafirlukast_SAR_2014_04.pdf
[544] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Azithromycin_2019_01__Art.46_PAR.pdf
[545] http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Pharmacovigilance_Legislation/PSUR/Summary_AR/zolmitriptan_SAR_2014_05.pdf
[546] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-e-5-8-july-2021-prac_pl.pdf
[547] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7_pl.pdf
[548] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7_pl.pdf
[549] https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december_pl.pdf